• HOME
  • NEWS
    • BIOENGINEERING
    • SCIENCE NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • FORUM
    • INSTAGRAM
    • TWITTER
  • CONTACT US
Friday, August 12, 2022
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
    • BIOENGINEERING
    • SCIENCE NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • FORUM
    • INSTAGRAM
    • TWITTER
  • CONTACT US
  • HOME
  • NEWS
    • BIOENGINEERING
    • SCIENCE NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • FORUM
    • INSTAGRAM
    • TWITTER
  • CONTACT US
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Science

The EMA accepts to assess the MAA from PharmaMar for Aplidin®

Bioengineer by Bioengineer
October 28, 2016
in Science
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

PharmaMar (MSE:PHM) has announced today that the European Medicines Agency (EMA) has accepted to assess the Marketing Authorization Application (MAA) for Aplidin® (plitidepsin) in combination with dexamethasone for the treatment of relapsed/refractory multiple myeloma (MM).

PharmaMar submitted the above mentioned application for the antitumor drug of marine origin, Aplidin®, in combination with dexamethasone given the positive results obtained from the ADMYRE study. Plitidepsin could be a therapeutic alternative for patients suffering from relapsed and/or refractory multiple myeloma.

After this acceptance, the EMA is going to start the assessment of this potential treatment for a type of blood cancer which accounts for 10% of all hematological malignancies.

The ADMYRE clinical trial is a randomized, Phase III study where the efficacy and safety of Aplidin® with dexamethasone versus dexamethasone alone in patients with relapsed/refractory MM after at least three, but no more than six, prior therapeutic regimens has been evaluated. The results of the ADMYRE study showed a statistically significant 35% reduction in the risk of progression or death over the comparator. The study met its primary endpoint.

###

About multiple myeloma

Multiple myeloma is a relatively uncommon type of blood cancer, which accounts for 10% of all hematological malignancies, this being caused by malignant plasma cells that very rapidly multiply. Normal plasma cells are white blood cells, which form part of the immune system, found in the bone marrow that produce the antibodies necessary for fighting infections. Abnormal cells produce a type of antibody that does not benefit the body and accumulate, thus preventing normal cells from functioning properly. In 2015, 26,850 new cases were diagnosed in the US, and about 11,200 people died from this disease. In Europe, the incidence is 4.5-6.0 out of 100 000 diagnosed per year, and the prevalence is 18 cases per 100 000 diagnosed over five years.

About APLIDIN® (plitidepsin)

Plitidepsin is an investigational anticancer agent of marine origin, originally obtained from the ascidian Aplidium albicans. It specifically binds to the eEF1A2 and targets the non-canonical role of this protein, resulting in tumor cell death via apoptosis (programed death). Plitidepsin is currently in clinical development for hematological cancers, including a Phase Ib trial in relapsed or refractory multiple myeloma as a triple combination of plitidepsin, bortezomib and dexamethasone, and a Phase II study in relapsed or refractory angioimmunoblastic T-cell lymphoma. Plitidepsin has received orphan drug designation in the European Union and the United States of America.

About PharmaMar

Headquartered in Madrid, PharmaMar is a world-leading biopharmaceutical company in the discovery and development of innovative marine-derived anticancer drugs. The company has an important pipeline of drug candidates and a robust R&D oncology program. PharmaMar develops and commercializes YONDELIS® in Europe and has three other clinical-stage programs under development for several types of solid and hematological cancers, PM1183, plitidepsin, and PM184. PharmaMar is a global biopharmaceutical company with subsidiaries in Germany, Italy, France, Switzerland, United Kingdom, Belgium and the United States. PharmaMar fully owns other companies: GENOMICA, Spain's leading molecular diagnostics company; Sylentis, dedicated to researching therapeutic applications of gene silencing (RNAi); and two other chemical enterprises, Zelnova Zeltia and Xylazel. To learn more about PharmaMar, please visit us at http://www.pharmamar.com.

Bibliography

http://www.cancer.org/cancer/multiplemyeloma/detailedguide/multiple-myeloma-what-is-multiple-myeloma
http://www.myeloma.org.uk/information/what-is-myeloma/
http://seer.cancer.gov/statfacts/html/mulmy.html
http://www.esmo.org/Guidelines/Haematological-Malignancies/Multiple-Myeloma
GLOBOCAN 2012, IARC – 6.9.2016

Media Contact

Paula Fernández Alarcón
[email protected]
34-638-796-215
@PhrmMar

http://www.pharmamar.com

Share12Tweet8Share2ShareShareShare2

Related Posts

blank

Senem SEZER won the Altın Kalem Master’s Thesis Award

March 22, 2022

Five or more hours of smartphone usage per day may increase obesity

July 25, 2019

NASA’s terra satellite finds tropical storm 07W’s strength on the side

July 25, 2019

NASA finds one burst of energy in weakening Depression Dalila

July 25, 2019
Please login to join discussion

POPULAR NEWS

  • Picture of the horse specimen.

    Ancient DNA clarifies the early history of American colonial horses

    56 shares
    Share 22 Tweet 14
  • Fatigue, headache among top lingering symptoms months after COVID

    40 shares
    Share 16 Tweet 10
  • Ill-fated ‘Into the Wild’ adventurer was victim of unfortunate timing, Oregon State study suggests

    39 shares
    Share 16 Tweet 10
  • Skin: An additional tool for the versatile elephant trunk

    38 shares
    Share 15 Tweet 10

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Tags

VirologyWeaponryVaccineWeather/StormsUrbanizationVaccinesUrogenital SystemViolence/CriminalsVehiclesUniversity of WashingtonVirusZoology/Veterinary Science

Recent Posts

  • A fresh look into grasslands as carbon sink
  • Researchers fabricate cobalt copper catalysts for methane on metal-organic framework Contributes to goal of methane production from carbon dioxide emissions
  • Virginia Tech veterinary college gets funding for research into parasite found in cats
  • China claims new world record for strongest steady magnetic field
  • Contact Us

© 2019 Bioengineer.org - Biotechnology news by Science Magazine - Scienmag.

No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

© 2019 Bioengineer.org - Biotechnology news by Science Magazine - Scienmag.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In